Show simple item record

dc.creatorĐedović, Neda
dc.creatorMansilla, María José
dc.creatorJevtić, Bojan
dc.creatorNavarro-Barriuso, Juan
dc.creatorSaksida, Tamara
dc.creatorMartínez-Cáceres, Eva M.
dc.creatorMiljković, Đorđe
dc.date.accessioned2019-03-07T09:26:10Z
dc.date.available2019-03-07T09:26:10Z
dc.date.issued2019
dc.identifier.urihttps://www.frontiersin.org/article/10.3389/fimmu.2019.00157/full
dc.identifier.urihttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6374627
dc.identifier.urihttps://ibiss-r.rcub.bg.ac.rs/handle/123456789/3280
dc.description.abstractDendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. Ethyl pyruvate (EP) is a redox analog of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment. We have recently shown that EP ameliorates experimental autoimmune encephalomyelitis, a multiple sclerosis murine model. Here, we expanded our study to its tolerogenic effects on DC. Phenotypic analysis has shown that DC obtained from mice or humans reduce expression of molecules required for T cell activation such as CD86, CD83, and HLA-DR under the influence of EP, while CD11c expression and viability of DC are not affected. Furthermore, EP-treated DC restrain proliferation and modulate cytokine production of allogeneic lymphocytes. These results demonstrate that EP has the ability to direct DC toward tolDC.
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173035/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173013/RS//
dc.relationPlan Nacional de I+D+I (PI14/01175), (PI17/01521)
dc.relationISCIII-Subdireccion General de Evaluacion
dc.relationFondo Europeo de Desarrollo Regional (FEDER)
dc.relationCost Action (BM1305)
dc.rightsopenAccess
dc.sourceFrontiers in Immunology
dc.subjectAutoimmunity
dc.subjectDendritic cells
dc.subjectEthyl pyruvate
dc.subjectImmune-regulation
dc.subjectTolerogenicity
dc.titleEthyl Pyruvate Induces Tolerogenic Dendritic Cells.
dc.typearticleen
dc.rights.licenseBY
dcterms.abstractСаксида, Тамара; Мансилла, Марíа Јосé; Мартíнез-Цáцерес, Ева М.; Ђедовић, Неда; Јевтић, Бојан; Наварро-Барриусо, Јуан; Миљковић, Ðорђе;
dc.rights.holder© 2019 Djedovic, Mansilla, Jevtić, Navarro-Barriuso, Saksida, Martínez-Cáceres and Miljković.
dc.citation.volume10
dc.identifier.doi10.3389/fimmu.2019.00157
dc.identifier.pmid30792716
dc.identifier.scopus2-s2.0-85061993185
dc.identifier.wos000458067300001
dc.citation.apaDjedovic, N., Mansilla, M. J., Jevtić, B., Navarro-Barriuso, J., Saksida, T., Martínez-Cáceres, E. M., & Miljković, Ð. (2019). Ethyl Pyruvate Induces Tolerogenic Dendritic Cells. Frontiers in Immunology, 10, 157.
dc.citation.vancouverDjedovic N, Mansilla MJ, Jevtić B, Navarro-Barriuso J, Saksida T, Martínez-Cáceres EM, Miljković Ð. Ethyl Pyruvate Induces Tolerogenic Dendritic Cells. Front Immunol. 2019;10:157.
dc.citation.spage157
dc.type.versionpublishedVersionen
dc.identifier.fulltexthttp://ibiss-r.rcub.bg.ac.rs//bitstream/id/4835/FrontImmunol_2019_10_157.pdf
dc.citation.rankM21


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record